German’s Bayer is eyeing a 13% increase in drug sales for its Japanese unit over the coming five years, according to a Bloomberg report, which should be spurred on by the launch of the thrombosis drug, BAY59-7939.
The company’s Japanese division recorded 2004 sales of 221 billion yen – up 2% on the previous year. The division’s healthcare subgroup achieved sales of 96 billion yen in 2004 – a 1% increase over the previous year, due mainly to the solid performance of pharmaceutical products despite a challenging business environment, and according to Bloomberg, the company is expecting pharmaceutical sales in this region to rise to 100 billion yen by the end of 2010.
The crop science subgroup dipped by 1% to 42 billion yen, but the material science subgroup recorded sales of 56 billion yen, which is up 10%.
